Literature DB >> 31425632

Interventions for ulceration and other skin changes caused by nerve damage in leprosy.

Liv Merete Reinar1, Louise Forsetlund, Linda Faye Lehman, Kjetil G Brurberg.   

Abstract

BACKGROUND: At the end of 2016, 145 countries reported to the World Health Organization (WHO) over 173,000 new cases of leprosy worldwide. In the past 20 years, over 16 million people have been treated for leprosy globally. The condition's main complications are injuries and ulceration caused by sensory loss from nerve damage. In this review we explored interventions to prevent or treat secondary damage to the skin in people affected by leprosy (Hansen's disease). This is an update of a Cochrane Review published in 2008.
OBJECTIVES: To assess the effects of education, information, self-care programmes, dressings, skin care, footwear and other measures for preventing and healing secondary damage to the skin in persons affected by leprosy. SEARCH
METHODS: We updated our searches of the following databases up to July 2018: the Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, AMED, LILACS, and CINAHL. We also searched five trial registers, three grey literature databases, and the reference lists of included studies for further references to relevant randomised controlled trials (RCTs). SELECTION CRITERIA: RCTs or quasi-RCTs or randomised cross-over trials involving anyone with leprosy and potential damage to peripheral nerves who was treated with any intervention designed to prevent damage, heal existing ulcers, and prevent development of new ulcers. Eligible comparisons were usual care, no interventions, or other interventions (e.g. other types of dressings or footwear). DATA COLLECTION AND ANALYSIS: We adhered to standard methodological procedures expected by Cochrane. Primary outcomes were prevention of ulcer(s), healing of existing ulcer(s) and adverse events. We used GRADE to assess the certainty of evidence for each outcome. MAIN
RESULTS: We included 14 trials (854 participants). Eleven studies reported on gender (men: 472, women: 157). Participant age varied from 18 to 74 years. Most participants had a single, mainly non-infected, wound on one foot, which had been there for less than a year. Only seven studies reported whole study duration (there was no follow-up post-treatment), which was on average six months (range: 1 to 12 months). The studies were conducted in Brazil, Ethiopia, Egypt, Indonesia, Mexico, South Korea, and India. Many 'Risk of bias' assessments were rated as unclear risk due to limited information. Six studies had high risk of bias in at least one domain, including selection and attrition bias.Thirteen studies evaluated different interventions for treating existing ulcers, one of them also evaluated prevention of new ulcers. One study aimed to prevent skin changes, such as cracking and fissures. Investigated interventions included: laser therapy, light-emitting diode (LED), zinc tape, intralesional pentoxifylline, pulsed magnetic fields, wax therapy, ketanserin, human amniotic membrane gel, phenytoin, plaster shoes, and footwear.We are uncertain about the following key results, as the certainty of evidence is very low. All time points were measured from baseline.Three studies compared zinc tape versus other interventions and reported results in favour of zinc tape. One study compared zinc tape versus magnesium sulphate: at one month the number of healed ulcers and reduction in mean ulcer area was higher with zinc tape (risk ratio (RR) 2.00, 95% confidence interval (CI) 0.43 to 9.21, and mean difference (MD) -14.30 mm², 95% CI -26.51 to -2.09, respectively, 28 participants). Another study compared zinc tape and povidone iodine and found that even though there was a greater reduction in ulcer area after six weeks of treatment with zinc tape, there was no clear difference due to the wide 95% CI (MD 128.00 mm², 95% CI -110.01 to 366.01; 38 participants). The third study (90 participants) compared adhesive zinc tape with gauze soaked in Eusol, and found the healing time for deep ulcers was less compared to zinc tape: 17 days (95% CI 12 to 20) versus 30 days (95% CI 21 to 63). Adverse events were only collected in the study comparing zinc tape with gauze soaked in Eusol: there were no signs of skin sensitisation in either group at two months.Two studies compared topical phenytoin versus saline dressing and reported results in favour of phenytoin. One study reported a greater mean percentage reduction of ulcer area after four weeks with phenytoin 2% (MD 39.30%, 95% CI 25.82 to 52.78; 23 participants), and the other study reported a greater mean percentage reduction of ulcer volume (16.60%) after four weeks with phenytoin (95% CI 8.46 to 24.74; 100 participants). No adverse events were observed with either treatment during the four-month treatment period (2 studies, 123 participants). Prevention of ulcers was not evaluated in these nor the zinc studies, as the interventions were not for preventative use.Two studies compared protective footwear (with or without self-care) with either 1) polyvinyl chloride (PVC) boots, or 2) pulsed magnetic fields plus self-care and protective footwear. In the study comparing canvas shoes versus PVC boots, none of the 72 participants with scars at the start of the study developed new ulcers over one-year follow-up. Healing of ulcers was assessed in 38 participants from this study, but we are unclear if there is a difference between groups. In the study comparing pulsed magnetic fields (in addition to self-care and protective footwear) to only self-care and footwear in 33 participants, we are uncertain if the mean volume of ulcers at four to five weeks' follow-up was different between groups; this study did not evaluate the prevention of ulcers. Information for adverse events was only reported in the study comparing canvas shoes with PVC boots; the authors stated that the PVC boots could become hot in strong sunlight and possibly burn the feet. AUTHORS'
CONCLUSIONS: Based on the available evidence, we could not draw firm conclusions about the effects of the included interventions. The main evidence limitations were high or unclear risk of bias, including selection, performance, detection, and attrition bias; imprecision due to few participants in the studies; and indirectness from poor outcome measurement and inapplicable interventions. Future research should clearly report important outcomes, such as adverse events, and assess widely available interventions, which should include treatments aimed at prevention. These trials should ensure allocation concealment, blinding, and an adequate sample size.

Entities:  

Year:  2019        PMID: 31425632      PMCID: PMC6699662          DOI: 10.1002/14651858.CD012235.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  54 in total

1.  Comparative value of active and passive surveillance over time in treated leprosy patients, in the prevention of further disability.

Authors:  A Gebre-Yesus; P Saunderson
Journal:  Lepr Rev       Date:  2001-06       Impact factor: 0.537

2.  New on-line parameters for analysis of dynamic foot pressures in neuropathic feet of Hansen's disease subjects.

Authors:  M M Bhatia; K M Patil
Journal:  J Rehabil Res Dev       Date:  1999-07

Review 3.  Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study.

Authors:  Julie Pildal; An-Wen Chan; Asbjørn Hróbjartsson; Elisabeth Forfang; Douglas G Altman; Peter C Gøtzsche
Journal:  BMJ       Date:  2005-04-07

Review 4.  Prevention and control of neglected tropical diseases: overview of randomized trials, systematic reviews and meta-analyses.

Authors:  Shanthi Kappagoda; John P A Ioannidis
Journal:  Bull World Health Organ       Date:  2014-03-13       Impact factor: 9.408

Review 5.  Future trends in the treatment of leprosy.

Authors:  S R Pattyn
Journal:  Trop Geogr Med       Date:  1994

6.  Simple plantar ulcers treated by below-knee plaster and moulded double-rocker plaster shoe--a comparative study.

Authors:  D J Pring; N Casiebanca
Journal:  Lepr Rev       Date:  1982-12       Impact factor: 0.537

Review 7.  Decompressive surgery for treating nerve damage in leprosy.

Authors:  Natasja H J Van Veen; Ton A R Schreuders; Willem J Theuvenet; Amit Agrawal; Jan Hendrik Richardus
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 8.  Leprosy.

Authors:  Warwick J Britton; Diana N J Lockwood
Journal:  Lancet       Date:  2004-04-10       Impact factor: 79.321

9.  Enhancing counselling strategies for leprosy patients through the participation scale.

Authors:  Neelmani Bense; Premal Das; Pamidipani Samuel Sundar Rao; Annamma Succinda John
Journal:  Lepr Rev       Date:  2013-09       Impact factor: 0.537

Review 10.  Corticosteroids for treating nerve damage in leprosy.

Authors:  N H J Van Veen; P G Nicholls; W C S Smith; J H Richardus
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18
View more
  4 in total

1.  Improving treatment outcomes for leprosy in Pernambuco, Brazil: a qualitative study exploring the experiences and perceptions of retreatment patients and their carers.

Authors:  Divya Khanna; Gilles de Wildt; Luiz Antonio Miranda de Souza Duarte Filho; Mitali Bajaj; Jo Freda Lai; Esme Gardiner; Andrea Maia Fernandes de Araújo Fonseca; Antje Lindenmeyer; Patrícia Sammarco Rosa
Journal:  BMC Infect Dis       Date:  2021-03-19       Impact factor: 3.090

Review 2.  Relationship between Plantar Pressure and Sensory Disturbance in Patients with Hansen's Disease-Preliminary Research and Review of the Literature.

Authors:  Syoichi Tashiro; Naoki Gotou; Yuki Oku; Takahiro Sugano; Takuya Nakamura; Hiromi Suzuki; Nao Otomo; Shin Yamada; Tetsuya Tsuji; Yutaka Asato; Norihisa Ishii
Journal:  Sensors (Basel)       Date:  2020-12-06       Impact factor: 3.576

3.  Presenting symptoms of leprosy at diagnosis: Clinical evidence from a cross-sectional, population-based study.

Authors:  Xiaohua Chen; Shun Zha; Tie-Jun Shui
Journal:  PLoS Negl Trop Dis       Date:  2021-11-23

4.  An individual randomised efficacy trial of autologous blood products, leukocyte and platelet-rich fibrin (L-PRF), to promote ulcer healing in leprosy in Nepal: the TABLE trial protocol.

Authors:  Indra B Napit; Dilip Shrestha; Jon Bishop; Sopna Choudhury; Santosh Dulal; Paramjit Gill; Eleni Gkini; Holly Gwyther; Deanna A Hagge; Karuna Neupane; Jo Sartori; Gemma Slinn; Samuel I Watson; Richard Lilford
Journal:  Trials       Date:  2021-07-15       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.